bacterial ribosomal proteins Inhibitors
2 drugsAbout bacterial ribosomal proteins
Bacterial ribosomal proteins are essential components of the bacterial ribosome, responsible for protein synthesis. Disrupting ribosome function halts bacterial growth, making these proteins attractive antibacterial targets.
While there is no genetic evidence directly linking bacterial ribosomal proteins to human diseases, their importance in bacterial survival is well-established, supporting their therapeutic relevance.
Bacterial ribosomal proteins are targeted by two FDA-approved small molecule drugs: MACRODANTIN (first approved in 1970) and MACROBID. Both drugs are marketed by ALMATICA for bacterial infection indications.
Top bacterial ribosomal proteins Drugs
The competitive landscape is highly concentrated, with ALMATICA being the only company with approved drugs.
High market concentration suggests potential entry barriers; focus on novel mechanisms or indications.
bacterial ribosomal proteins Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets bacterial ribosomal proteins, using small molecule modality.
Explore alternative modalities like peptides or oligonucleotides to differentiate from existing therapies.
bacterial ribosomal proteins Clinical Trials 34 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on bacterial ribosomal proteins. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 1 | 0 | 2 | 100% |
| Phase 2 | 2 | 1 | 0 | 1 | 100% |
| Phase 3 | 6 | 3 | 1 | 2 | 75% |
| Phase 4 | 23 | 13 | 2 | 8 | 87% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
bacterial ribosomal proteins Drug Approval Timeline (1991 - 1991)
The approval timeline spans 22 years, with the first drug approved in 1970 and the most recent in 1991.
The long gap since the last approval suggests potential saturation; consider targets with more recent activity.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 29 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on bacterial ribosomal proteins. A trial counts if an approved drug acting on bacterial ribosomal proteins is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.